Researchers assessed the impact of TNF inhibitor use during the 3 years after being diagnosed with early-stage cancer among patients with RA. Data for the retrospective cohort study were sourced from ...

As the goal of RA treatment is to induce disease remission ... was as effective as the combination of methotrexate and a TNF inhibitor in patients with early, active RA and poor prognostic ...

TNF inhibitor use demonstrates no negative impact ... The study included 1,981 patients with RA split into three different groups — those with early-stage colorectal cancer (n = 514), lung ...

Patients with RA aged at least 65 years who were diagnosed with cancer between 2014 and 2019 ... This reduction was more pronounced among estrogen receptor-positive cases, though further research is ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th ...

Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.